ARTICLE | Clinical News
Amevive alefacept (LFA-3/IgG): Completed Phase III studies
January 22, 2001 8:00 AM UTC
Biogen Inc. (BGEN), Cambridge, Mass. Product: Amevive alefacept ( LFA-3/IgG) Business: Autoimmune/Inflammation, Dermatology Therapeutic category: Immune modulation Target: CD2 receptor on T cells De...